D1 receptor Inhibitors
1 drugsAbout D1 receptor
The D1 receptor is a G protein-coupled receptor in the dopamine receptor family, crucial for CNS functions like motor control, reward, and cognition.
The D1 receptor is a potential therapeutic target due to its functional importance, but currently lacks genetic evidence linking it directly to specific diseases.
D1 receptor currently has one FDA-approved drug, DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, a small molecule approved in 1983 and marketed by Pfizer.
Top D1 receptor Drugs
Pfizer is the only company with an approved drug targeting the D1 receptor.
Low market competition suggests a high barrier to entry or limited commercial viability for new D1 receptor drugs.
D1 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets D1 receptor, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel biologics targeting the D1 receptor.
D1 receptor Clinical Trials 27 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on D1 receptor. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 5 | 1 | 0 | 83% |
| Phase 2 | 9 | 4 | 3 | 1 | 57% |
| Phase 3 | 4 | 2 | 1 | 1 | 67% |
| Phase 4 | 8 | 4 | 0 | 4 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
D1 receptor Drug Approval Timeline (1983 - 1983)
Shock
The first and only drug was approved in 1983, DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER.
The absence of recent approvals indicates potential saturation or challenges in developing new D1 receptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 22 (4 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on D1 receptor. A trial counts if an approved drug acting on D1 receptor is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.